Drug intelligence / Profile preview

GB-NOP

Development stage: Preclinical
Lead developer: GlycosBio
Administration: Oral

Overview

GB-NOP is a lipid-engineered nutraceutical candidate developed by GlycosBio, utilizing the company's proprietary Activated Oil System technology. This functional food product is designed for oral administration to support child brain development. The Activated Oil System is a delivery platform intended to enhance the bioavailability and absorption of specific lipids or nutrients. Within GlycosBio's pipeline, GB-NOP is categorized under microbiome-related therapies, suggesting a potential role in modulating the gut-brain axis or providing essential fatty acids necessary for cognitive and neurological maturation in children. It is currently in clinical development as part of GlycosBio's specialized lipid-engineering portfolio.

Beyond the preview

Go deeper on GB-NOP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-NOP.

Explore the full profile